Following $1.9B buyout, Sanofi shutters Kadmon's NY site and chops 25 staffers
Sanofi CEO Paul Hudson is on a mission to reshape the company. Last year, that involved shelling out $1.9 billion for Kadmon and its newly approved Rezurock — but apparently, the former biotech’s New York site is not part of Hudson’s vision.
The pharma giant is shutting down Kadmon’s New York plant in Q3 and laying off 25 employees, according to New York state documents. The layoffs will begin July 1, and continue through April 1, 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.